MCID: MNN032
MIFTS: 46

Meningococcal Meningitis

Categories: Infectious diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Meningococcal Meningitis

MalaCards integrated aliases for Meningococcal Meningitis:

Name: Meningococcal Meningitis 12 58 15 17 71 32
Meningitis, Meningococcal 74 43
Meningitis Meningococcal 54

Characteristics:

Orphanet epidemiological data:

58
meningococcal meningitis
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-9/100000 (New Zealand),1-9/1000000 (United States);

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:0080176
ICD9CM 34 036.0
MeSH 43 D008585
ICD10 32 A39.0
MESH via Orphanet 44 D008585
ICD10 via Orphanet 33 A39.0+ G01*
UMLS via Orphanet 72 C0025294
Orphanet 58 ORPHA33475
UMLS 71 C0025294

Summaries for Meningococcal Meningitis

Disease Ontology : 12 A bacterial meningitis that has material basis in Neisseria meningitidis infection.

MalaCards based summary : Meningococcal Meningitis, also known as meningitis, meningococcal, is related to meningococcemia and haemophilus influenzae. An important gene associated with Meningococcal Meningitis is CFP (Complement Factor Properdin), and among its related pathways/superpathways are Innate Immune System and Tuberculosis. The drugs Lactitol and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include testes, b cells and spinal cord, and related phenotype is renal/urinary system.

Wikipedia : 74 Meningococcal disease describes infections caused by the bacterium Neisseria meningitidis (also termed... more...

Related Diseases for Meningococcal Meningitis

Diseases related to Meningococcal Meningitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 233)
# Related Disease Score Top Affiliating Genes
1 meningococcemia 31.4 MBL2 CFP
2 haemophilus influenzae 30.8 TLR2 CFH
3 meningitis 30.8 TLR9 TLR4 TLR2 MBL2 CFP C3
4 complement component 5 deficiency 30.1 CFP CFHR2 C3
5 neisseria meningitidis infection 29.9 TLR4 TLR2 MBL2 DHPS CFP C3
6 glomerulonephritis 29.9 TLR9 MBL2 CFP CFH C3
7 membranoproliferative glomerulonephritis 29.9 CFP CFHR2 CFH C3
8 streptococcus pneumonia 29.8 TLR9 TLR4 TLR2
9 bacterial meningitis 29.8 TLR9 TLR4 TLR2 MBL2 CFP C3
10 plague 29.8 TLR9 TLR4 TLR2
11 listeriosis 29.7 TLR4 TLR2 MBL2
12 complement component 3 deficiency 29.6 MBL2 CFP CFHR2 C3
13 candidiasis 29.6 TLR4 TLR2 MBL2
14 bacterial infectious disease 29.3 TLR9 TLR4 TLR2 MBL2 CFP
15 complement deficiency 29.2 MBL2 CFP CFHR2 CFH C7 C6
16 malaria 29.1 TLR9 TLR4 TLR2 MBL2 DHPS CFH
17 otitis media 29.1 TLR4 TLR2 MBL2 C3
18 thrombocytopenia 28.8 TLR9 TLR4 TLR2 CFH C3
19 eye disease 28.7 TLR4 TLR2 CFHR2 CFH C3
20 meningococcal infection 10.6
21 pericarditis 10.5
22 branchiootic syndrome 1 10.4
23 mannose-binding lectin deficiency 10.4 MBL2 CFP
24 exanthem 10.4
25 endophthalmitis 10.3
26 waterhouse-friderichsen syndrome 10.3
27 ataxia and polyneuropathy, adult-onset 10.3
28 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.3
29 purpura 10.3
30 pleural empyema 10.3
31 arthritis 10.3
32 immunodeficiency due to a late component of complement deficiency 10.3 C7 C6
33 disseminated intravascular coagulation 10.2
34 toxic shock syndrome 10.2
35 vasculitis 10.2
36 atypical hemolytic uremic syndrome with complement gene abnormality 10.2 CFH C3
37 yemenite deaf-blind hypopigmentation syndrome 10.2
38 complement component 6 deficiency 10.2
39 purpura fulminans 10.2
40 subdural empyema 10.2
41 paraplegia 10.2
42 pneumococcal meningitis 10.2
43 genetic atypical hemolytic-uremic syndrome 10.2 CFH C3
44 diffuse glomerulonephritis 10.1 CFP C3
45 complement component 7 deficiency 10.1
46 complement component 9 deficiency 10.1
47 hydrops, lactic acidosis, and sideroblastic anemia 10.1
48 sensorineural hearing loss 10.1
49 hydrocephalus 10.1
50 tetanus 10.1

Graphical network of the top 20 diseases related to Meningococcal Meningitis:



Diseases related to Meningococcal Meningitis

Symptoms & Phenotypes for Meningococcal Meningitis

MGI Mouse Phenotypes related to Meningococcal Meningitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.23 BAMBI C3 CFH DHPS MBL2 TLR2

Drugs & Therapeutics for Meningococcal Meningitis

Drugs for Meningococcal Meningitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
2 Immunoglobulins Phase 4
3 Antibodies Phase 4
4 Cathartics Phase 4
5 Gastrointestinal Agents Phase 4
6 Laxatives Phase 4
7
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 15589840
8
Aluminum hydroxide Approved, Investigational Phase 2, Phase 3 21645-51-2
9
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
10
Cobalamin Experimental Phase 3 13408-78-1 6857388
11 Vitamin B 12 Phase 3
12 Vitamin B12 Phase 3
13 Vaccines Phase 3
14 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
15 Immunologic Factors Phase 3
16 Pharmaceutical Solutions Phase 3
17
Aluminum sulfate Approved Phase 2 10043-01-3
18 Antipyretics Phase 2
19
Phenylalanine Approved, Investigational, Nutraceutical 63-91-2 6140
20 Antibiotics, Antitubercular

Interventional clinical trials:

(show top 50) (show all 130)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Single Center, Open-Label, Controlled, Randomized Study to Evaluate the Memory Response of Children Previously Vaccinated With Chiron Meningococcal C Conjugate Vaccine, Menjugate® and Describe the Kinetic of the Antibody Response and Maturation on Days 2-7 and 28 After Challenge With Pasteur Merieux Meningococcal A/C Polysaccharide Vaccine or Menjugate® Unknown status NCT00262015 Phase 4
2 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier Completed NCT02633787 Phase 4
3 Immunogenicity and Safety of Two-Dose Series of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284; Menactra®) in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
4 Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin for Contacts of Cases of Meningococcal Meningitis as an Epidemic Response Completed NCT02724046 Phase 4 Ciprofloxacin
5 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine (Tdap, Boostrix®) and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine (Gardasil®) in Healthy Adolescents When Administered With MenACWY Conjugate Vaccine Completed NCT01424644 Phase 4
6 Meningococcal (Groups A, C, Y, W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) Post-Marketing Safety Study in Healthy Children (2-11 Years), Adolescents (12-17 Years) and Adults (18-55 Years) in the Philippines Completed NCT01270503 Phase 4
7 Assay of the Immunogenicity of Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine in Africa Completed NCT00271479 Phase 4
8 A Phase III/IV Randomised Open-label Study and Comparison of the Immunogenicity and Safety of a Single Adolescent Booster Dose of a Meningococcal Group C Conjugate-containing Booster Vaccine (Meningitec™, OR NeisVac-C™ , OR Menitorix™), When Given Concurrently With an Acellular Pertussis-containing Booster Vaccine (Repevax™ or IPV-Boostrix™) Completed NCT02526394 Phase 4 Pertussis containing vaccine
9 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
10 Evaluation of the Effect of Tetravalent (A, C, Y, W-135) Meningococcal Conjugate Vaccine on Serogroup-Specific Carriage of Neisseria Meningitidis Completed NCT00119080 Phase 4
11 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the First and the Third Immunization With Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Infants at 2, 3 and 4 Months of Age Completed NCT00310700 Phase 4
12 A Phase IV,Multi-Center,Open-Label,Unrandomized Study to Evaluate the Persistence of Antibody Response to N.Meningitidis Group C,Before & After 2 Doses of the Conjugate Pneumococcal Vaccine,in Children Seven Months & Older Who Previously Received Immunization With Chiron Meningococcal C Conjugate Vaccine & a Hexavalent Infant Vaccine According to the Applicable Infant Immunization Schedule Completed NCT00316654 Phase 4
13 A Phase IV, Single Centre, Open-label Study to Evaluate the Persistence of Antibodies in Adolescents 14-16 Years of Age, Vaccinated With Chiron Meningococcal C Conjugate Vaccine During the 1999-2001 UK MenCC Immunization Campaign, at One Year After Either a Challenge Dose of Aventis Pasteur MSD Meningococcal A/C Polysaccharide Vaccine or a Booster Dose of MenC Vaccine, in Parallel to Subjects Aged 11-20 Evaluated at 4 Years After Vaccination During the 1999-2001 UK MenCC Immunization Campaign Completed NCT00310687 Phase 4
14 A Single Centre, Open-label, Randomised Clinical Study to Investigate Meningococcal Serogroup A and C Saccharide Specific B Cell Responses in Adult Volunteers to One of Three Regimens of Meningococcal ACWY Conjugate Vaccine or Meningococcal ACWY Polysaccharide Vaccine Priming Doses Followed by a Booster Dose of the Meningococcal ACWY Conjugate Vaccine Completed NCT01593514 Phase 4
15 A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C Saccharide Component of Chiron's Meningococcal C Conjugate Vaccine Administered to Healthy Children at Least 12 Months of Age After Priming With a Commercially Available Men ACWY Conjugate Vaccine at 2, 3 and 4 Months of Age Completed NCT00310713 Phase 4
16 A Sourcing Study to Collect Human Biological (Serum) Samples From Healthy Adults Recruiting NCT03493919 Phase 4
17 Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population (ProPositive Study) Recruiting NCT03682939 Phase 4
18 Postmarketing Surveillance Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in the Republic of Korea Active, not recruiting NCT02864927 Phase 4
19 Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin Prophylaxis as a Response to a Meningococcal Meningitis Epidemic Withdrawn NCT03431675 Phase 4 Ciprofloxacin
20 A Phase 3, Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants Completed NCT00474526 Phase 3
21 A Randomized, Open-Label Trial of NeisVac-C Vaccine to Evaluate Immunological Interference With Hepatitis B, Inactivated Polio and Acellular Pertussis Vaccines in Healthy Infants Completed NCT00161928 Phase 3
22 A Phase IIIb, Open-Label, Controlled, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine Completed NCT01148017 Phase 3
23 An Open-Label, Multi-Center Study to Evaluate the Persistence Of Antibody Responses Among Adolescents Who Previously Received Novartis MenACWY Conjugate Vaccine or Commercially Available MenACWY Conjugate Vaccine Completed NCT00856297 Phase 3
24 A Phase 3, Multi-center Study to Evaluate Lot to Lot Consistency, Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults and Compare to the Safety and Immune Response to a Licensed Conjugate Meningococcal ACWY Vaccine Completed NCT00450437 Phase 3
25 A Phase 3, Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 11 to 55 Years of Age in Korea Completed NCT01274897 Phase 3
26 A Phase 3, Single-Center, Open-label, Controlled, Randomized Study to Evaluate the Safety and Immunogenicity of Novartis Men ACWY Vaccine Administered Either Alone or Concomitantly With a Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine and Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine in Healthy Adolescents Completed NCT00518180 Phase 3
27 A Phase IIIb, Open Label, Multi Center Extension Study of V72_28 to Assess Antibody Persistence, and the Safety and Tolerability of a Booster Dose After the Completion of the Vaccination Course in Study V72_28 Completed NCT01894919 Phase 3
28 Phase 3b, Open Label, Uncontrolled, Single-arm, Single-centre Study to Evaluate the Safety of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Healthy Adults From 18 to 50 Years of Age and to Collect Blood Donations to Develop Vaccines Against Neisseria Meningitidis Completed NCT02305446 Phase 3
29 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Other Pediatric Vaccines in Healthy Toddlers Completed NCT03205371 Phase 3
30 A Phase III, Single Center, Open Label, Uncontrolled Study to Evaluate the Immunogenicity, Safety and Tolerability, of the Chiron Meningococcal C Conjugate Vaccine When Administered to Healthy Premature and Non Premature Children at 3, 5, 11 Months of Age Concomitantly With a Hexavalent Infant Vaccine Completed NCT00310674 Phase 3
31 Immunogenicity and Safety of a Single Dose of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects Completed NCT01519713 Phase 3
32 Safety Study of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered With Other Pediatric Vaccines to Healthy Toddlers Completed NCT00483574 Phase 3
33 A Phase 3, Partially Blinded, Randomized, Multi-Center, Controlled Study to Evaluate Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants Completed NCT00657709 Phase 3
34 A Phase 3, Multi-center Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adults and Compare to the Safety and Immune Response of a Licensed Conjugate Meningococcal ACWY Vaccine in Subjects Aged 19-55 Years of Age and to a Licensed Polysaccharide Vaccine in Subjects Aged 56-65 Years of Age. Completed NCT00474487 Phase 3
35 A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine Administered to Healthy Infants and Toddlers Completed NCT00667602 Phase 3
36 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults Age 56 Years and Older Completed NCT02842866 Phase 3
37 A Phase 2b/3, Multi-Center, Extension Study of V72P10 to Assess Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10. Completed NCT01148524 Phase 2, Phase 3
38 A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Safety And Tolerability Of A Meningococcal Serogroup B Bivalent Recombinant Lipoprotein (rlp2086) Vaccine Given In Healthy Subjects Aged Greater Than Or Equal To 10 To Less Than 26 Years Completed NCT01352793 Phase 3
39 A Phase 3b, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life. Completed NCT01214837 Phase 3
40 A Phase 3b, Single-Center, Open-label Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-risk Adults Completed NCT01478347 Phase 3
41 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Adults Completed NCT01466387 Phase 3
42 A Phase 3, Multi-Center, Observer Blind, Controlled, Randomized Study to Compare the Immunogenicity and Safety of the Concomitant Administration of a Combined Tetanus, Reduced Diphtheria, and Acellular Pertussis (Tdap) Vaccine and Chiron (Now Novartis) Meningococcal ACWY Conjugate Vaccine, With Either One Dose of Acellular Pertussis (Tdap) Vaccine, or One Dose of Chiron (Now Novartis) Meningococcal ACWY Conjugate Vaccine, in Healthy Subjects Aged 11-25 Years Completed NCT00329901 Phase 3
43 Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine 134612 With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults at 9-25 Years of Age Completed NCT01755689 Phase 3
44 Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children 2 to 9 Years of Age Completed NCT03077438 Phase 3
45 A Phase 3, Randomized, Comparative, Multicenter Observer-Blind Study Evaluating the Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years Completed NCT01423084 Phase 3
46 An Immunogenicity and Safety Evaluation of Two Doses of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) Given to Healthy Subjects at 9 and 12 Months of Age Completed NCT00384397 Phase 3
47 A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years Completed NCT01339923 Phase 3
48 A Phase 3, Open Label, Multi-Center, Extension Study to Assess Antibody Persistence and Response to a Third or Fifth Dose of Novartis Meningococcal B Recombinant Vaccine in 4-Year-Old Children Who Previously Participated in Study V72P12E1 Completed NCT01717638 Phase 3
49 Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults Aged 10 to 55 Years Completed NCT02842853 Phase 3
50 Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults Completed NCT02752906 Phase 3

Search NIH Clinical Center for Meningococcal Meningitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Chloramphenicol sodium succinate

Cochrane evidence based reviews: meningitis, meningococcal

Genetic Tests for Meningococcal Meningitis

Anatomical Context for Meningococcal Meningitis

MalaCards organs/tissues related to Meningococcal Meningitis:

40
Testes, B Cells, Spinal Cord, Neutrophil, Brain, Kidney, Skin

Publications for Meningococcal Meningitis

Articles related to Meningococcal Meningitis:

(show top 50) (show all 1474)
# Title Authors PMID Year
1
[Predisposing factors of community acquired bacterial meningitis (excluding neonates)]. 54 61
19419829 2009
2
[Immunology in the medical practice. XXVII. Mannose-binding lectin, an important link for nonspecific or hereditary immune reaction]. 54 61
10897301 2000
3
Association of familial deficiency of mannose-binding lectin and meningococcal disease. 54 61
10509505 1999
4
Validation of a new Rapid Detection Test for the detection of Neisseria meningitidis A/C/W/X/Y antigens in cerebrospinal fluid. 61
31915288 2020
5
Differences in the courses of meningococcal and pneumococcal cerebrospinal meningitis. 61
31956973 2020
6
Development a multi-epitope driven subunit vaccine for immune response reinforcement against Serogroup B of Neisseria meningitidis using comprehensive immunoinformatics approaches. 61
31394292 2019
7
Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery. 61
31762464 2019
8
Bacterial Meningitis Epidemiology in Five Countries in the Meningitis Belt of Sub-Saharan Africa, 2015-2017. 61
31671441 2019
9
A case report of multiple cerebral abscess formation complicating serogroup B Neisseria meningitidis meningitis. 61
31638913 2019
10
Subdural and subarachnoid empyema as a complication of an acute meningococcal meningitis. 61
31630118 2019
11
Spatiotemporal Analysis of Serogroup C Meningococcal Meningitis Spread in Niger and Nigeria and Implications for Epidemic Response. 61
31671446 2019
12
Meningococcal Meningitis Outbreaks in the African Meningitis Belt After Meningococcal Serogroup A Conjugate Vaccine Introduction, 2011-2017. 61
31671449 2019
13
Meningitis vaccines in children: what have we achieved and where next? 61
31335439 2019
14
MenAfriNet: A Network Supporting Case-Based Meningitis Surveillance and Vaccine Evaluation in the Meningitis Belt of Africa. 61
31671453 2019
15
Neisseria meningitidis Serogroup W Meningitis Epidemic in Togo, 2016. 61
31671438 2019
16
Epidemiology of Bacterial Meningitis in the Nine Years Since Meningococcal Serogroup A Conjugate Vaccine Introduction, Niger, 2010-2018. 61
31671439 2019
17
Changes in the Molecular Epidemiology of Pediatric Bacterial Meningitis in Senegal After Pneumococcal Conjugate Vaccine Introduction. 61
31505635 2019
18
Reactive vaccination as a control strategy for pneumococcal meningitis outbreaks in the African meningitis belt: Analysis of outbreak data from Ghana. 61
29371015 2019
19
A case of a FilmArray® ME false negative in meningococcal meningitis. 61
31102602 2019
20
Meningococcal meningitis presenting postinfant group B meningococcal immunisation. 61
30518518 2019
21
Epidemiological burden of meningococcal disease in Latin America: A systematic literature review. 61
31085314 2019
22
Gauging the epidemic potential of a widely circulating non-invasive meningococcal strain in Africa. 61
31454306 2019
23
A Systematic Review for Vaccine-Preventable Diseases on Ships: Evidence for Cross-Border Transmission and for Pre-Employment Immunization Need. 61
31366029 2019
24
Anti-Factor H Antibody Reactivity in Young Adults Vaccinated with a Meningococcal Serogroup B Vaccine Containing Factor H Binding Protein. 61
31270173 2019
25
Outbreaks of meningococcal meningitis in non-African countries over the last 50 years: a systematic review. 61
30937163 2019
26
Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. 61
30987851 2019
27
Virulence Traits of a Serogroup C Meningococcus and Isogenic cssA Mutant, Defective in Surface-Exposed Sialic Acid, in a Murine Model of Meningitis. 61
30718288 2019
28
Increasing the number of contacts generated during contact tracing interviews. 61
30295153 2019
29
Analysis of a meningococcal meningitis outbreak in Niger - potential effectiveness of reactive prophylaxis. 61
30856166 2019
30
Fatal meningococcal meningitis in a 2-year-old child: A case report. 61
30863763 2019
31
Meningococcal purpura fulminans and severe myocarditis with clinical meningitis but no meningeal inflammation: a case report. 61
30871501 2019
32
Meningococcal Meningitis. 61
30860561 2019
33
Subdural effusion and ischemic stroke complicating meningococcal meningitis in an adult. 61
30497911 2019
34
[Analysis of epidemic characteristics for meningococcal meningitis in China during 2015-2017]. 61
30744289 2019
35
Pediatric meningococcocal meningitis in the acute phase: how much does it cost? 61
30760306 2019
36
[Efficacy, safety, and cost-effectiveness of meningococcal vaccines]. 61
30744260 2019
37
[Efficacy, safety, and cost-effectiveness of meningococcal vaccines]. 61
30744287 2019
38
Induced Pluripotent Stem Cell-Derived Brain Endothelial Cells as a Cellular Model to Study Neisseria meningitidis Infection. 61
31191497 2019
39
Meningococcal pneumonia: a review. 61
31463180 2019
40
Evaluation of integrated disease surveillance and response (IDSR) core and support functions after the revitalisation of IDSR in Uganda from 2012 to 2016. 61
30626358 2019
41
Carbohydrates in Vaccine Development. 61
31267872 2019
42
[Genotypes of Neisseria meningitidis isolates in patients with meningococcal meningitis in Paraguay, 1996-2015Genótipos de Neisseria meningitidis isolados de pacientes com doença meningocócica no Paraguai, 1996-2015]. 61
31093234 2019
43
Neisseria meningitidis and cytomegalovirus simultaneous detection in the filmarray meningitis/encephalitis panel and its clinical relevance. 61
31193598 2019
44
Intraventricular empyema caused by Neisseria meningitidis. 61
30788218 2019
45
The attitudes, behaviors, and knowledge of healthcare professionals towards the diagnosis, treatment, and prevention of bacterial meningitis in Turkey. 61
30192703 2019
46
Vaccine-preventable disease control in the People's Republic of China: 1949-2016. 61
30497834 2018
47
Differential influences of complement on neutrophil responses to Neisseria meningitidis infection. 61
30476070 2018
48
Infectious meningitis and encephalitis in adults in Denmark: a prospective nationwide observational cohort study (DASGIB). 61
29409994 2018
49
Rare vascular complication of acute meningococcal meningitis in a child. 61
30373900 2018
50
Epidemics of meningococcal meningitis in Northern Nigeria focus on preventive measures. 61
30588927 2018

Variations for Meningococcal Meningitis

Expression for Meningococcal Meningitis

Search GEO for disease gene expression data for Meningococcal Meningitis.

Pathways for Meningococcal Meningitis

Pathways related to Meningococcal Meningitis according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.8 TLR9 TLR4 TLR2 SIGLEC5 MBL2 CFP
2 11.99 TLR9 TLR4 TLR2 C3
3 11.85 TLR4 TLR2 MBL2 C3
4
Show member pathways
11.82 MBL2 CFH C7 C6 C3
5
Show member pathways
11.81 TLR9 TLR4 TLR2
6 11.79 MBL2 CFHR2 CFH C7 C6 C3
7
Show member pathways
11.76 TLR9 TLR4 TLR2
8 11.64 MBL2 CFH C3
9
Show member pathways
11.56 MBL2 CFP CFH C7 C6 C3
10 11.55 TLR9 TLR4 TLR2 C3
11 11.39 TLR4 TLR2 C3
12 11.28 TLR9 TLR4 TLR2
13
Show member pathways
11.13 MBL2 CFP CFH C7 C6 C3

GO Terms for Meningococcal Meningitis

Cellular components related to Meningococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane attack complex GO:0005579 8.62 C7 C6

Biological processes related to Meningococcal Meningitis according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.06 TLR9 TLR4 TLR2 MBL2 C6 C3
2 defense response to bacterium GO:0042742 9.94 TLR9 TLR4 MBL2 CFP
3 complement activation, classical pathway GO:0006958 9.89 MBL2 C7 C6 C3
4 immune response GO:0006955 9.87 TLR9 TLR4 TLR2 CFP C7 C6
5 positive regulation of inflammatory response GO:0050729 9.82 TLR9 TLR4 TLR2
6 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.8 TLR9 TLR4 TLR2
7 positive regulation of interleukin-6 production GO:0032755 9.79 TLR9 TLR4 TLR2
8 positive regulation of tumor necrosis factor production GO:0032760 9.79 TLR9 TLR4 TLR2
9 toll-like receptor signaling pathway GO:0002224 9.75 TLR9 TLR4 TLR2
10 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.73 TLR9 TLR4 TLR2
11 positive regulation of interleukin-8 production GO:0032757 9.72 TLR9 TLR4 TLR2
12 positive regulation of interleukin-12 production GO:0032735 9.67 TLR9 TLR4 TLR2
13 cytolysis GO:0019835 9.66 C7 C6
14 positive regulation of interleukin-8 secretion GO:2000484 9.66 TLR4 TLR2
15 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.65 TLR9 TLR4
16 regulation of cytokine secretion GO:0050707 9.65 TLR9 TLR2
17 response to molecule of bacterial origin GO:0002237 9.65 TLR9 TLR2
18 positive regulation of interferon-beta production GO:0032728 9.65 TLR9 TLR4 TLR2
19 cellular response to lipoteichoic acid GO:0071223 9.63 TLR4 TLR2
20 positive regulation of interferon-beta biosynthetic process GO:0045359 9.63 TLR9 TLR4
21 positive regulation of interleukin-10 production GO:0032733 9.63 TLR9 TLR4 TLR2
22 regulation of complement activation GO:0030449 9.63 CFP CFHR2 CFH C7 C6 C3
23 positive regulation of interleukin-18 production GO:0032741 9.61 TLR9 TLR2
24 positive regulation of chemokine production GO:0032722 9.61 TLR9 TLR4 TLR2
25 tumor necrosis factor production GO:0032640 9.6 TLR9 TLR2
26 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.58 TLR9 TLR4 TLR2
27 positive regulation of toll-like receptor signaling pathway GO:0034123 9.57 TLR9 TLR2
28 complement activation, alternative pathway GO:0006957 9.56 CFP CFH C7 C3
29 positive regulation of matrix metallopeptidase secretion GO:1904466 9.54 TLR4 TLR2
30 I-kappaB phosphorylation GO:0007252 9.54 TLR9 TLR4 TLR2
31 positive regulation of cellular response to macrophage colony-stimulating factor stimulus GO:1903974 9.52 TLR4 TLR2
32 positive regulation of activation of membrane attack complex GO:0001970 9.51 C6 C3
33 complement activation GO:0006956 9.43 MBL2 CFP CFH C7 C6 C3
34 innate immune response GO:0045087 9.28 TLR9 TLR4 TLR2 MBL2 CFP CFH

Molecular functions related to Meningococcal Meningitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling pattern recognition receptor activity GO:0008329 8.96 TLR9 TLR2
2 lipopolysaccharide receptor activity GO:0001875 8.62 TLR4 TLR2

Sources for Meningococcal Meningitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....